Innate Pharma initiated with a Buy at BTIG

BTIG analyst Justin Zelin initiated coverage of Innate Pharma (IPHA) with a Buy rating and $8 price target Innate is a clinical-stage biotechnology company developing therapies for cancer and autoimmune disease, the analyst tells investors in a research note. The firm believes IPH4502 could address post Padcev treated bladder cancer patients and other Nectin-4 low tumor types. It sees the Initial Phase 1 data in late 2025 or early 2026 as a catalyst for the shares.